Researchers at Harvard and Beth Israel Deaconess Medical Center have identified the biological reason some people never fully recover from COVID-19, and the answer points toward actual treatments.
The study, led by Dan H. Barouch, analyzed blood samples from over 140 participants and found something unexpected: long COVID isn't caused by virus hiding in the body. Instead, it's driven by the immune system getting stuck in a state of chronic inflammation—essentially, the body's defense system never receives the signal to stand down.
This distinction matters enormously. For years, clinical trials have chased the wrong target, using antiviral drugs to eliminate residual virus. But if the virus is already gone and the inflammation remains, those drugs won't help. "There is currently no specific treatment for long COVID, which affects millions of people in the United States," Barouch said. "Our findings show that long COVID is characterized by persistent activation of chronic inflammatory pathways, which defines new potential therapeutic targets."
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThe team used what they call a "multi-omic" approach—essentially, they looked at the immune system from every angle at once. They examined immune responses, viral markers, gene expression, and plasma proteins in people with long COVID, comparing them to those who were never infected, acutely infected, or fully recovered. This comprehensive view revealed a clear pattern: long COVID patients showed signs of chronic inflammation, immune system depletion, and disruptions in how their cells process energy.
One finding stood out: people whose immune systems showed the most inflammation early in their infection were more likely to develop lingering symptoms months later. This suggests that how your body responds in the first weeks of COVID may predict whether you'll recover fully or struggle with long-term effects.
"Integrating multi-omic data gave us a unified view of long COVID's immune landscape, enabling us to identify key pathways that can be therapeutically targeted," said Malika Aid Boudries, the study's first author and an assistant professor of medicine at Harvard Medical School.
The researchers identified specific immune proteins and molecular signatures that could become targets for new drugs—treatments designed not to kill a virus, but to quiet an overactive immune system and help it reset. This is a fundamentally different approach, and it opens the door to therapies that might actually work for the millions of Americans still struggling with fatigue, brain fog, and breathing difficulties years after infection.
